维普期刊资源整合服务平台（V6.5）

21篇 您的检索式：作者名="Mathijssen R H"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Clinical pharmacokinetics and metabolism of irinotecan( CPT-ll ) 显示文摘	MATHIJSSEN R H J van ALPHEN R J YERWEI J J et a1	2001	Clin Cancer Res2001，7，8：	1
2	Irinotecan pathway genotype analysis to predict pharmacokinetics 显示文摘	MATHIJSSEN R H MARSH S KARLSSON M O	2003	Clin Cancer Res2003，9，9：	1
3	Moving towards dose individualization of tyrosine kinase inhibitors 显示文摘	KLUMPEN H J SAMER C F MATHIJSSEN R H	2011	Cancer Treat Rev2011，37，4：	1
4	ABCG2 pharmacogenetics:ethnic differences in allele frequency and assessment of influence on irinotecan disposition显示文摘	DE JONG F A MARSH S MATHIJSSEN R H	2004	Clin Cancer Res2004，10，17：	1
5	Danusertib, an aurora kinase inhibitor 显示文摘	MEULENBELD H J MATHIJSSEN R H VERWEIJ J	2012	Expert Opin Investig Drugs2012，21，3：	1
6	Prophylaxis of irinotecan - induced diarrhea with neomycin and potential role for UGT1A1 * 28 genotype screening: a double - blind, randomized, placebo - controlled study 显示文摘	De Jong F A Kehrer D F Mathijssen R H	2006	Oncologist2006，11，8：	1
7	Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGTI A1 * 28 genotype screening: a double-blind, randomized, placebo-controlled study 显示文摘	DE JONG F A KEHRER D F MATHIJSSEN R H	2006	Oncologist2006，11，8：	1
8	ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition显示文摘	DE JONG F A MARSH S MATHIJSSEN R H	2004	Clin Cancer Res2004，10，17：	1
9	Prediction of irinotecan pharmaeokinetics by use of cytochrome P450 3A4 phenotyping probes显示文摘	MATHIJSSEN R H DE JONG F A VAN SCHAIK R H	2004	J Natl Cancer Inst2004，96，21：	1
10	Irinotecan pathway genotype analysis to predict pharmacokinetics显示文摘	Mathijssen R H Marsh S Karlsson M O	2003	Clin Cancer Res2003，15，9：	1
11	Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)显示文摘	Mathijssen R H van Alphen R J Verweij J	2001	Clinical Cancer Research2001，7，9：	1
12	Irinotecan pathway genotype analysis to predict pharmacokinetics 显示文摘	MATHIJSSEN R H MARSH S KARLSSON M O	2003	Clin Cancer Res2003，9，9：	1
13	Contribution of organic cation transporter 2 ( OCT2 ) to cisplatin- induced nephrotoxicity显示文摘	FILIPSKI K K MATHIJSSEN R H MIKKELSEN T S	2009	Clin Pharmacol Ther2009，86，4：	1
14	Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening:a double-blind,randomized,placebo-controlled study显示文摘	De Jong F A Kehrer D F Mathijssen R H	2006	Oncologist2006，11，8：	1
15	Prophy- laxis of irinotecan-induced diarrhea with neomycin and po- tential role for UGT1AI' 28 genotype screening: a double- blind, randomized, placebo-controlled study显示文摘	de Jong F A Kehrer D F Mathijssen R H	2006	Oncologist2006，11，8：	1
16	Clinical pharmacokinetics and metabolism of irinotecan(CPT-11)显示文摘	MATHIJSSEN R H ALPHEN R J V VERWEIJ J	2001	Clin Cancer Res2001，7，8：	1
17	Ethnic differences in allele frequency and assessment of influence on irinotecan disposition显示文摘	DE JONG F A MARSH S MATHIJSSEN R H	2004	Clin Cancer Res2004，10，17：	1
18	Clinical pharmacokinetics of irinotecan and its metabolites in relation WITH DIARRHEA 显示文摘	XIE R MATHIJSSEN R H SPARREBOOM A	2002	Clin Pharmacol Ther2002，72，3：	1
19	A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan 显示文摘	VAN DER BOL J M MATHIJSSEN R H CREEMERS G J	2010	Clin Cancer Res2010，16，2：	1
20	Cigarette smok- ing and irinotecan treatment:Pharmacokinetic interaction and effects on neutropenia显示文摘	van der Bol J M Mathijssen R H Loos W J	2007	J Clin Oncol2007，25，19：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示